Teresa Lee

Assistant Professor

Fox Chase Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (6)

Year:

2026

Year:

2026

11507 Background: Advanced uterine leiomyosarcoma (uLMS) is an aggressive malignancy with poor prognosis. Standard-of-care treatments, including trabectedin (Tb) or pazopanib (P), provide median progression-free survival (PFS) of 3-4 months (mo) and objective response rates (ORR) of ~11%. Homologous recombination deficiency (HRD) in a subset of uLMS supports the use of PARP inhibitors combined with DNA-damaging agents. Preclinical studies demonstrated synergistic activity of olaparib and temozolomide (T+O), and a prior single-arm Phase II study of T+O showed promising efficacy independent of an established biomarker, warranting further investigation in a randomized setting. Methods: Alliance A092104 is a Phase II/III trial evaluating olaparib (200 mg BID) plus temozolomide (75 mg/m² daily, days 1-7, every 21 days) versus investigator’s choice of Tb or P in patients (pts) with advanced uLMS who progressed on ≥2 prior systemic therapies. Stratification factors included ECOG (0-1 vs. 2) and prior lines (2 vs. ≥3). The Phase II (Phase III) primary endpoint was PFS (OS), with a planned suspension of accrual at the end of Phase II. A total of 70 evaluable pts (58 PFS events) were needed to detect an improvement in PFS from 4 vs. 8 mo with power of 90% and 1-sided type I error of 10%, with futility assessed after 29 PFS events. Upon meeting the Phase II futility threshold for PFS, the trial was permanently closed. Data were released from the data and safety monitoring board. Pts continue to be followed for outcomes. Results: 74 pts enrolled (Arm 1: T+O, n = 37; Arm 2: investigator’s choice, n = 37 (Tb, 18; P, 13; 6 pts did not start treatment). The arms were balanced for baseline demographics except race, with the T+O arm having a higher proportion of black/African American (29.7% vs. 16.2%). 21 pts remain on treatment. Hematologic adverse events (AEs) were more frequent in the T+O arm, with Grade 4 neutropenia (19.5%) and thrombocytopenia (8.3%) both managed by dose reductions. Non-hematologic Grade 3 AEs were higher in the investigator’s choice arm (45.2% vs. 13.9%). No Grade 5 AEs were reported. In the first 70 pts, with a median follow-up of 5.9 mo, and 39 total PFS events, the median PFS was 3.2 mo (95% CI: 2.0-NE) for T+O versus 5.6 mo (95% CI: 2.8-NE) for investigator’s choice (HR = 1.00; 95% CI: 0.60-2.17; 1-sided stratified log rank p = 0.50). Within Arm 2, the median PFS for Tb and P were respectively 5.6 (95% CI: 3.1-NE) and 3.8 (95% CI: 1.5-NE) mo. 3 pts in the T+0 arm and 1 patient in the investigator’s choice arm (Tb) had a confirmed partial response. Conclusions: The trial did not meet its primary endpoint of PFS in Phase II. This suggests that a biomarker may be needed before there is further exploration of PARP inhibitor-based regimens in uLMS. Overall survival and analysis of tissue-based biomarkers will be presented. Clinical trial information: NCT05432791 .

Year:

2025

e18020 Background: Nasopharyngeal carcinoma (NPC) is an aggressive and unique subtype of head and neck cancer, largely associated with Epstein-Barr virus (EBV) and endemic in East Asian populations. Current treatment paradigms are based on studies predominantly involving these populations, with limited data on patients from other racial or ethnic groups. We present a retrospective analysis from our institution, which primarily serves an African American (AA) population. Methods: We evaluated a single-center’s cancer registry data from January 2013 to December 2023, identifying 30 patients with histologically confirmed NPC. Detailed chart reviews were conducted to assess demographics, clinical features, and treatment patterns. All tumors were restaged using the AJCC 8th edition criteria. Results: Of the 30 patients, 16 were AA, 8 of European ancestry (EA), 5 of Asian ancestry (AS), and 1 unknown. EBV status (EBER IHC) was evaluable in 28/30 cases, with EBV positivity observed in 12/16 (75%) AA, 4/7 (57%) EA, and 5/5 (100%) AS patients. The mean age at diagnosis was 55.43 years (range from 24-82 years). Alcohol (50%) and tobacco consumption (50%) were common. Majority of tumors (23/30) were classified as non-keratinizing subtype, with no notable racial differences. Most patients presented with locally advanced (LA) stage III or IVA (83%, 25/30) and none had distant metastases at initial presentation. For LA, non-metastatic NPCs treated with definitive intent (n=23), only five patients received the current standard-of-care regimen as established in 2019 (Induction chemotherapy [I] → Chemoradiation [CRT]), achieving the best outcomes (median overall survival [mOS] not reached). Outcomes for CRT → Adjuvant chemotherapy (AC) showed a median OS of 82 months, while CRT alone had the poorest outcomes (mOS 39 months, p=0.1851). AA patients associated with worse OS (HR = 2.71, p = 0.050), although the small sample size limited robust multivariate analysis. For patients treated with definitive intent, recurrence was noted in 10/23 (43%) with distant recurrence/metastases being most common (8/10, 80%). 9/10 patients who had recurrences belonged to CRT (3) or CRT->AC (6) treatment group. Conclusions: This analysis reports outcomes for NPC in a cancer center with predominantly AA population, demonstrating worse survival outcomes compared to other groups. Additionally, although limited by size, our data indicates the importance of appropriate treatment sequencing to achieve optimal outcomes.

Year:

2025

Year:

2024

Myxoid leiomyosarcoma (MLS) is a rare but well‐documented tumor that often portends a poor prognosis compared to the conventional leiomyosarcoma. This rare sarcoma has been reported in the uterus, external female genitalia, soft tissue, and other locations. However, a definite rectal MLS has not been reported. Recently five cases of MLS were reported to harbor PLAG1 fusions ( TRPS1::PLAG1, RAD51B::PLAG1, and TRIM13::PLAG1 ). In this report, we present a case of rectal MLS with a novel MIR143HG::PLAG1 fusion detected by RNA next‐generation sequencing.

Year:

2024

Collaborators (1)

Pamela N. Munster

Professor

Stanford University

UNITED STATES
View details